Paradigm BioCapital Advisors LP 13D and 13G filings for Viridian Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2024-11-14 4:33 pm Sale |
2024-09-30 | 13G | Viridian Therapeutics, Inc. VRDN |
Paradigm BioCapital Advisors LP | 3,509,253 4.600% |
-1,795,060 (-33.84%) |
Filing |
| 2024-02-14 4:08 pm Purchase |
2023-12-31 | 13G | Viridian Therapeutics, Inc. VRDN |
Paradigm BioCapital Advisors LP | 5,304,313 9.990% |
2,993,615 (+129.55%) |
Filing |
| 2023-05-11 4:26 pm Purchase |
2023-05-01 | 13G | Viridian Therapeutics, Inc. VRDN |
Paradigm BioCapital Advisors LP | 2,310,698 5.400% |
419,531 (+22.18%) |
Filing |
| 2023-02-14 4:59 pm Purchase |
2022-12-31 | 13G | Viridian Therapeutics, Inc. VRDN |
Paradigm BioCapital Advisors LP | 1,891,167 4.700% |
682,116 (+56.42%) |
Filing |
| 2022-02-14 06:12 am Purchase |
2021-12-31 | 13G | Viridian Therapeutics, Inc. VRDN |
Paradigm BioCapital Advisors LP | 1,209,051 5.570% |
1,209,051 (New Position) |
Filing |